278 related articles for article (PubMed ID: 23942301)
1. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitors for the treatment of ovarian cancer.
Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
5. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
8. [First-line bevacizumab in ovarian cancer].
Mäenpää J
Duodecim; 2011; 127(19):2037-44. PubMed ID: 22073535
[TBL] [Abstract][Full Text] [Related]
9. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
10. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
14. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
15. New ways to successfully target tumor vasculature in ovarian cancer.
Yang X; Shen F; Hu W; Coleman RL; Sood AK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
18. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
19. [Gynecologic cancer].
Sugiyama T; Takeuchi S; Fukagawa T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):157-61. PubMed ID: 24743194
[TBL] [Abstract][Full Text] [Related]
20. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
